2018 Press Releases

Keyword Search
 

November 07, 2018

Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14 read more

November 06, 2018

Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update read more

November 06, 2018

Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200 read more

October 22, 2018

Protagonist Therapeutics Presents Clinical Data from the PROPEL Study of PTG-100 in Ulcerative Colitis at United European Gastroenterology Week read more

October 08, 2018

Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting read more

September 27, 2018

Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 read more

September 24, 2018

Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1 read more

September 19, 2018

Protagonist Therapeutics Reports Granting of Inducement Award read more

September 06, 2018

Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300 read more

September 06, 2018

Protagonist Therapeutics Expands Intellectual Property Portfolio read more

August 17, 2018

Protagonist Therapeutics Reports Granting of Inducement Award read more

August 07, 2018

Protagonist Therapeutics Reports Second Quarter 2018 Financial Results read more

August 06, 2018

Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis read more

August 06, 2018

Protagonist Therapeutics Secures $22 Million Equity Financing read more

June 18, 2018

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting read more

June 06, 2018

Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference read more

June 01, 2018

Protagonist Therapeutics Reports Granting of Inducement Award read more

May 24, 2018

Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer read more

May 17, 2018

Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association read more

May 16, 2018

Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors read more

May 09, 2018

Protagonist Therapeutics Reports First Quarter 2018 Financial Results read more

May 03, 2018

Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference read more

March 26, 2018

Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis read more

March 09, 2018

Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference read more

March 07, 2018

Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results read more

March 06, 2018

FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia read more

March 01, 2018

Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference read more

March 01, 2018

Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow read more

January 31, 2018

Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference read more

January 04, 2018

Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 read more